NPI: 1710918545 · SACRAMENTO, CA 95817 · General Acute Care Hospital · NPI assigned 07/06/2006
Authorized official TROVATTEN, TAMMY controls 20+ related entities in our dataset. Read more
| Authorized Official | TROVATTEN, TAMMY (VICE PRESIDENT, GOV'T REIMBURSEMENT) |
| NPI Enumeration Date | 07/06/2006 |
Other providers sharing the same authorized official: TROVATTEN, TAMMY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 279,710 | $18.64M |
| 2019 | 321,471 | $17.44M |
| 2020 | 316,393 | $17.56M |
| 2021 | 409,472 | $24.61M |
| 2022 | 433,216 | $30.09M |
| 2023 | 490,457 | $37.18M |
| 2024 | 454,608 | $32.02M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 0450 | Emergency room services | 108,272 | 92,579 | $24.25M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 17,260 | 16,618 | $6.80M |
| J9271 | Injection, pembrolizumab, 1 mg | 669 | 538 | $5.89M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 22,600 | 19,517 | $4.93M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 26,102 | 24,565 | $4.82M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 60,513 | 46,781 | $4.78M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2,004 | 1,879 | $4.44M |
| 0121 | 635 | 511 | $4.33M | |
| 99199 | Unlisted special service, procedure or report | 65,644 | 49,054 | $4.23M |
| 70450 | Computed tomography, head or brain; without contrast material | 13,006 | 12,496 | $3.78M |
| 77386 | 7,086 | 660 | $3.63M | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 68,026 | 58,328 | $3.27M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 2,267 | 2,081 | $3.02M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 33,446 | 29,095 | $2.98M |
| 72125 | Computed tomography, cervical spine; without contrast material | 6,262 | 6,037 | $2.91M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 18,027 | 13,826 | $2.67M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 56,837 | 48,838 | $2.40M |
| 99201 | 30,592 | 23,606 | $2.39M | |
| 80053 | Comprehensive metabolic panel | 105,981 | 87,854 | $2.38M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 6,954 | 6,704 | $2.36M |
| 96375 | Therapeutic injection; each additional sequential IV push | 32,717 | 25,024 | $2.36M |
| 96361 | Intravenous infusion, hydration; each additional hour | 27,186 | 21,645 | $2.34M |
| Z7500 | 63,606 | 54,600 | $2.14M | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1,983 | 1,549 | $1.98M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 3,627 | 3,549 | $1.89M |
| 90791 | Psychiatric diagnostic evaluation | 9,362 | 8,441 | $1.85M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 7,984 | 5,566 | $1.84M |
| J3490 | Unclassified drugs | 92,536 | 54,928 | $1.76M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 151,260 | 122,579 | $1.66M |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 1,537 | 456 | $1.44M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 5,682 | 5,598 | $1.42M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1,061 | 1,034 | $1.40M |
| 0510 | 32,653 | 28,635 | $1.33M | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 13,539 | 12,743 | $1.26M |
| 71046 | Radiologic examination, chest; 2 views | 25,268 | 23,904 | $1.15M |
| 99499 | 12,352 | 8,697 | $1.14M | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 550 | 495 | $1.13M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 11,408 | 8,884 | $1.06M |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 30,863 | 30,079 | $1.06M |
| 80048 | Basic metabolic panel (calcium, ionized) | 60,106 | 50,265 | $925K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 12,662 | 8,193 | $910K |
| J9299 | Injection, nivolumab, 1 mg | 111 | 77 | $901K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 10,538 | 9,401 | $895K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 2,165 | 2,130 | $875K |
| 71045 | Radiologic examination, chest; single view | 19,361 | 18,227 | $868K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 27,323 | 25,593 | $811K |
| 70486 | 2,555 | 2,503 | $804K | |
| 86803 | 30,508 | 29,941 | $785K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 14,484 | 13,645 | $771K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2,129 | 2,092 | $728K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 17,514 | 13,478 | $691K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 19,761 | 18,512 | $670K |
| 93325 | 4,719 | 4,590 | $666K | |
| 73564 | 6,633 | 5,740 | $642K | |
| 83690 | 42,853 | 39,316 | $627K | |
| 70498 | 1,171 | 1,141 | $586K | |
| J7050 | Infusion, normal saline solution, 250 cc | 19,903 | 11,926 | $566K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 5,601 | 5,337 | $538K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 2,461 | 2,430 | $532K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 471 | 424 | $521K |
| 0762 | 1,438 | 802 | $520K | |
| 0761 | 8,947 | 7,120 | $508K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1,307 | 1,291 | $475K |
| 0760 | 75,033 | 56,511 | $466K | |
| 82248 | 51,568 | 46,890 | $465K | |
| Z7502 | 12,270 | 11,593 | $463K | |
| 72141 | 1,015 | 998 | $454K | |
| 84484 | 25,685 | 19,159 | $453K | |
| 73610 | 7,195 | 6,286 | $452K | |
| 93970 | 1,957 | 1,923 | $450K | |
| J2350 | Injection, ocrelizumab, 1 mg | 26 | 24 | $449K |
| P9016 | Red blood cells, leukocytes reduced, each unit | 934 | 811 | $443K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2,190 | 2,106 | $427K |
| 70496 | 1,094 | 1,059 | $427K | |
| 76825 | 1,186 | 1,107 | $412K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2,052 | 1,984 | $411K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 8,300 | 7,931 | $406K |
| 73110 | 6,640 | 5,460 | $399K | |
| 73080 | 5,094 | 4,530 | $380K | |
| 83880 | 11,738 | 10,124 | $376K | |
| 82805 | 6,585 | 6,027 | $366K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 859 | 813 | $361K |
| 73630 | 7,584 | 6,670 | $359K | |
| 73130 | 6,806 | 5,753 | $357K | |
| 73030 | 5,033 | 4,503 | $342K | |
| 73590 | 6,149 | 5,379 | $341K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 3,749 | 3,647 | $335K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 8,316 | 7,945 | $328K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 13,950 | 10,967 | $325K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 1,229 | 1,210 | $307K |
| 76770 | 3,195 | 3,120 | $307K | |
| 88185 | 603 | 484 | $307K | |
| 93971 | 2,210 | 2,138 | $307K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 9,632 | 5,754 | $305K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 5,537 | 4,475 | $298K |
| 0360 | 1,913 | 1,444 | $295K | |
| 0270 | 2,424 | 1,823 | $276K | |
| 86850 | 23,590 | 19,407 | $276K | |
| 84443 | Thyroid stimulating hormone (TSH) | 15,472 | 14,984 | $270K |
| 93975 | 954 | 935 | $269K | |
| 73090 | 5,016 | 4,238 | $262K | |
| 70491 | 1,029 | 1,000 | $261K | |
| 70487 | 763 | 749 | $259K | |
| 0370 | 411 | 395 | $258K | |
| 76830 | Ultrasound, transvaginal | 2,475 | 2,415 | $255K |
| 93320 | 2,618 | 2,577 | $250K | |
| 0160 | 3,916 | 2,358 | $248K | |
| 86900 | 24,380 | 20,006 | $241K | |
| 88341 | 1,327 | 980 | $237K | |
| J0185 | Injection, aprepitant, 1 mg | 1,402 | 887 | $236K |
| 0710 | 2,647 | 2,565 | $230K | |
| 96415 | 4,000 | 2,964 | $228K | |
| Z7506 | 1,750 | 1,717 | $227K | |
| 83735 | 28,539 | 20,526 | $225K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 5,409 | 4,277 | $222K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1,914 | 1,873 | $221K |
| 85027 | 23,801 | 19,201 | $219K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 3,366 | 2,669 | $215K |
| 73700 | 723 | 687 | $202K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 25,296 | 19,924 | $200K |
| 96367 | 3,602 | 2,582 | $196K | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | 65 | 50 | $195K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 2,953 | 2,304 | $194K |
| 73060 | 2,787 | 2,549 | $190K | |
| J0897 | Injection, denosumab, 1 mg | 203 | 196 | $189K |
| 90715 | 4,187 | 4,110 | $188K | |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 56 | 52 | $184K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 15,607 | 14,515 | $181K |
| 84702 | 2,797 | 2,384 | $181K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 7,060 | 6,283 | $176K |
| G0378 | Hospital observation service, per hour | 2,627 | 2,225 | $175K |
| 73502 | 3,072 | 2,862 | $169K | |
| 83605 | 9,390 | 8,052 | $168K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 8,240 | 8,124 | $167K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1,609 | 1,602 | $166K |
| 77336 | 2,597 | 1,182 | $164K | |
| 77334 | 564 | 400 | $158K | |
| 74018 | 3,663 | 3,385 | $156K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1,753 | 1,729 | $153K |
| 71250 | 832 | 822 | $153K | |
| J0485 | Injection, belatacept, 1 mg | 239 | 139 | $150K |
| 72156 | 239 | 237 | $146K | |
| 81001 | 23,712 | 21,829 | $146K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2,795 | 2,713 | $144K |
| 74183 | 631 | 623 | $144K | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 101 | 37 | $139K |
| 0301 | 786 | 738 | $137K | |
| 82803 | 4,271 | 3,926 | $135K | |
| 86901 | 24,542 | 20,084 | $131K | |
| 87522 | Neg quan hep c or qual rna | 2,068 | 2,009 | $131K |
| 72100 | 2,685 | 2,630 | $128K | |
| 82962 | 22,885 | 17,407 | $128K | |
| 76801 | 1,476 | 1,367 | $127K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 15,169 | 14,792 | $127K |
| 76827 | 1,176 | 1,099 | $124K | |
| J1170 | Injection, hydromorphone, up to 4 mg | 10,535 | 8,132 | $124K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 16,587 | 14,833 | $123K |
| 0636 | 613 | 570 | $123K | |
| J1815 | Injection, insulin, per 5 units | 2,780 | 1,718 | $122K |
| 73552 | 3,481 | 3,132 | $120K | |
| 72082 | 1,989 | 1,965 | $118K | |
| 86923 | 1,487 | 927 | $116K | |
| 77301 | 98 | 97 | $114K | |
| J0178 | Injection, aflibercept, 1 mg | 62 | 61 | $113K |
| 96417 | 2,275 | 1,510 | $111K | |
| 86140 | 14,057 | 13,239 | $111K | |
| 76870 | 1,139 | 1,099 | $110K | |
| 87040 | 5,331 | 3,917 | $109K | |
| 0460 | 1,835 | 1,599 | $109K | |
| Z9725 | 2,475 | 2,453 | $106K | |
| 94010 | 2,880 | 2,858 | $105K | |
| J2704 | Injection, propofol, 10 mg | 9,025 | 6,650 | $104K |
| 81025 | 13,344 | 12,587 | $101K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 2,251 | 1,577 | $100K |
| 85610 | 20,790 | 17,751 | $99K | |
| 77300 | 362 | 338 | $98K | |
| 85730 | 8,437 | 7,943 | $96K | |
| 86780 | 7,683 | 7,379 | $95K | |
| 94618 | 1,103 | 1,086 | $92K | |
| 72070 | 996 | 955 | $91K | |
| 96409 | 2,763 | 1,487 | $90K | |
| 72040 | 1,521 | 1,470 | $90K | |
| 95782 | 78 | 78 | $86K | |
| 92504 | 2,826 | 2,706 | $86K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 4,258 | 4,089 | $83K |
| 0250 | 1,381 | 1,200 | $83K | |
| 76536 | 1,472 | 1,435 | $82K | |
| 0700 | 1,265 | 1,143 | $82K | |
| 92557 | 1,193 | 1,173 | $82K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1,271 | 1,233 | $80K |
| 86003 | 730 | 678 | $80K | |
| 84100 | 16,064 | 12,531 | $78K | |
| 74174 | 241 | 237 | $76K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 15,157 | 12,814 | $75K |
| 87077 | 6,089 | 5,839 | $75K | |
| 86922 | 1,011 | 638 | $75K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 5,422 | 4,628 | $74K |
| 87799 | 1,608 | 1,251 | $74K | |
| 88342 | 2,422 | 2,226 | $74K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 4,954 | 3,118 | $73K |
| 76857 | 1,096 | 1,075 | $73K | |
| 83970 | 2,363 | 2,302 | $72K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 592 | 590 | $71K |
| 85652 | 11,546 | 10,922 | $71K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 8,906 | 3,755 | $71K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 5,717 | 5,198 | $70K |
| Z7514 | 1,245 | 674 | $70K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 2,989 | 2,671 | $70K |
| 81003 | 16,915 | 16,014 | $69K | |
| 72197 | 275 | 274 | $69K | |
| 85379 | 3,778 | 3,583 | $67K | |
| 84439 | 7,128 | 6,923 | $61K | |
| 72157 | 109 | 107 | $61K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 118 | 117 | $60K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 12,248 | 11,069 | $60K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 2,465 | 2,290 | $60K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 278 | 261 | $59K |
| J0875 | Injection, dalbavancin, 5 mg | 13 | 13 | $59K |
| 87186 | 4,300 | 4,124 | $59K | |
| 87631 | 657 | 629 | $58K | |
| 95816 | 618 | 614 | $58K | |
| 86480 | 1,453 | 1,430 | $55K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 97 | 94 | $54K |
| 36415 | Collection of venous blood by venipuncture | 7,747 | 6,642 | $53K |
| J3370 | Injection, vancomycin hcl, 500 mg | 1,890 | 1,407 | $52K |
| 97750 | 1,049 | 906 | $52K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 599 | 595 | $52K |
| 72158 | 68 | 68 | $52K | |
| 96411 | 673 | 457 | $51K | |
| 82784 | 3,878 | 3,394 | $49K | |
| 72146 | 121 | 121 | $49K | |
| 72131 | 158 | 158 | $49K | |
| 87493 | 1,172 | 1,148 | $48K | |
| 77295 | 40 | 26 | $48K | |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 26 | 16 | $47K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 7,951 | 5,964 | $47K |
| 72170 | 871 | 841 | $47K | |
| 93226 | 731 | 726 | $47K | |
| 76512 | 709 | 568 | $47K | |
| 80197 | 3,960 | 2,592 | $46K | |
| J3590 | Unclassified biologics | 331 | 232 | $46K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 7,344 | 5,485 | $46K |
| 87081 | 4,100 | 3,651 | $46K | |
| A4649 | Surgical supply; miscellaneous | 1,078 | 1,026 | $46K |
| Z7512 | 1,774 | 1,746 | $45K | |
| 80061 | Lipid panel | 6,073 | 5,953 | $44K |
| 96523 | 1,382 | 1,030 | $44K | |
| 99070 | 1,374 | 1,319 | $44K | |
| 83516 | 2,702 | 1,925 | $43K | |
| 87340 | 3,325 | 3,241 | $41K | |
| 81002 | 10,369 | 7,900 | $39K | |
| 72050 | 760 | 752 | $37K | |
| 87070 | 3,020 | 2,866 | $37K | |
| 82728 | 4,621 | 4,416 | $36K | |
| 88184 | 572 | 463 | $36K | |
| Z7508 | 617 | 610 | $36K | |
| 80076 | 2,985 | 2,839 | $36K | |
| 92567 | 921 | 910 | $36K | |
| A4217 | Sterile water/saline, 500 ml | 2,216 | 1,939 | $35K |
| 76820 | 374 | 303 | $35K | |
| J9267 | Injection, paclitaxel, 1 mg | 217 | 123 | $34K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2,459 | 1,254 | $34K |
| 94726 | 795 | 789 | $34K | |
| 77290 | 132 | 93 | $34K | |
| 82140 | 1,656 | 1,536 | $33K | |
| 86235 | 627 | 540 | $32K | |
| 82550 | 3,821 | 3,344 | $32K | |
| 59025 | Fetal non-stress test | 2,377 | 1,143 | $32K |
| 81514 | 109 | 107 | $31K | |
| 82570 | 8,332 | 7,294 | $31K | |
| 80164 | 1,317 | 1,163 | $31K | |
| 84466 | 3,554 | 3,492 | $31K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 354 | 265 | $31K |
| J2777 | Injection, faricimab-svoa, 0.1 mg | 12 | 12 | $30K |
| 96368 | 1,030 | 682 | $30K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 529 | 495 | $30K |
| J1650 | Injection, enoxaparin sodium, 10 mg | 1,896 | 719 | $30K |
| 93356 | 808 | 805 | $29K | |
| J0690 | Injection, cefazolin sodium, 500 mg | 3,355 | 2,890 | $29K |
| 93017 | 349 | 345 | $29K | |
| 94729 | 821 | 814 | $28K | |
| 77338 | 105 | 101 | $28K | |
| 92582 | 341 | 337 | $28K | |
| 72110 | 465 | 463 | $28K | |
| 70544 | 139 | 138 | $28K | |
| 87497 | 597 | 375 | $27K | |
| 93922 | 628 | 613 | $27K | |
| 96416 | 586 | 318 | $26K | |
| J1644 | Injection, heparin sodium, per 1000 units | 2,774 | 1,431 | $26K |
| 73000 | 473 | 432 | $26K | |
| 0306 | 545 | 529 | $25K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 3,524 | 2,193 | $25K |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 473 | 450 | $25K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 968 | 963 | $24K |
| 76942 | 367 | 348 | $24K | |
| 93225 | 497 | 494 | $24K | |
| J2060 | Injection, lorazepam, 2 mg | 2,888 | 2,256 | $23K |
| 0305 | 692 | 654 | $23K | |
| 95886 | 466 | 368 | $23K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 124 | 123 | $23K |
| 73562 | 926 | 867 | $23K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 564 | 561 | $23K |
| 88108 | 1,288 | 1,171 | $23K | |
| 87653 | 907 | 894 | $21K | |
| J1953 | Injection, levetiracetam, 10 mg | 298 | 253 | $21K |
| Z5924 | 295 | 295 | $21K | |
| 88313 | 885 | 503 | $21K | |
| 92552 | 1,065 | 1,038 | $20K | |
| J1756 | Injection, iron sucrose, 1 mg | 256 | 141 | $20K |
| 73560 | 1,027 | 709 | $20K | |
| 86706 | 2,052 | 1,999 | $20K | |
| 83540 | 4,197 | 4,108 | $20K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 3,787 | 1,721 | $19K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 65 | 64 | $19K |
| L8699 | Prosthetic implant, not otherwise specified | 13 | 13 | $19K |
| 82330 | 790 | 650 | $19K | |
| 93296 | 1,061 | 1,060 | $19K | |
| 84156 | 6,806 | 5,719 | $18K | |
| 73600 | 696 | 595 | $18K | |
| 94060 | 381 | 378 | $18K | |
| 92134 | 3,001 | 2,905 | $18K | |
| 96450 | 65 | 62 | $18K | |
| 90686 | 2,952 | 2,884 | $18K | |
| J9190 | Injection, fluorouracil, 500 mg | 1,044 | 401 | $18K |
| 92060 | 1,244 | 1,215 | $17K | |
| 87205 | 2,873 | 2,672 | $17K | |
| 82378 | 1,217 | 1,135 | $17K | |
| 0750 | 191 | 185 | $17K | |
| 86704 | 1,618 | 1,577 | $17K | |
| 83615 | 2,972 | 2,351 | $16K | |
| 95819 | 207 | 206 | $16K | |
| X4301 | 170 | 170 | $16K | |
| 86038 | 1,384 | 1,367 | $16K | |
| J2785 | Injection, regadenoson, 0.1 mg | 124 | 123 | $16K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 32 | 29 | $16K |
| 84703 | 325 | 310 | $16K | |
| 92579 | 286 | 282 | $15K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 102 | 102 | $15K |
| 76000 | 357 | 351 | $15K | |
| 82746 | 1,306 | 1,293 | $15K | |
| J9045 | Injection, carboplatin, 50 mg | 460 | 292 | $14K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 526 | 525 | $14K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 529 | 439 | $14K |
| 85007 | 3,588 | 2,877 | $14K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | 32 | 26 | $14K |
| 92650 | 43 | 42 | $14K | |
| 73140 | 451 | 415 | $14K | |
| 86360 | 369 | 363 | $14K | |
| J0475 | Injection, baclofen, 10 mg | 13 | 13 | $13K |
| 86160 | 757 | 729 | $13K | |
| 76642 | 305 | 296 | $13K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 891 | 856 | $12K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 1,679 | 1,014 | $12K |
| J1790 | Injection, droperidol, up to 5 mg | 566 | 522 | $12K |
| 92555 | 502 | 495 | $12K | |
| 77387 | 51 | 13 | $12K | |
| 85045 | 2,631 | 2,103 | $12K | |
| 59841 | 37 | 37 | $11K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 1,128 | 1,079 | $11K |
| J1630 | Injection, haloperidol, up to 5 mg | 1,460 | 1,103 | $11K |
| 72190 | 267 | 254 | $11K | |
| 87507 | 31 | 31 | $11K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 3,774 | 1,814 | $11K |
| 86359 | 371 | 366 | $11K | |
| 82607 | 1,515 | 1,502 | $11K | |
| 0300 | 660 | 626 | $11K | |
| 90670 | 214 | 195 | $11K | |
| 96401 | 535 | 277 | $10K | |
| Z7510 | 176 | 175 | $10K | |
| 70543 | 40 | 38 | $10K | |
| 82533 | 682 | 613 | $10K | |
| 84403 | 726 | 685 | $10K | |
| J3360 | Injection, diazepam, up to 5 mg | 266 | 235 | $10K |
| 74178 | 54 | 53 | $9K | |
| 88307 | 251 | 221 | $9K | |
| 83520 | 615 | 589 | $9K | |
| 96379 | 256 | 232 | $9K | |
| 82785 | 558 | 552 | $9K | |
| J9370 | Vincristine sulfate, 1 mg | 1,036 | 742 | $9K |
| J1940 | Injection, furosemide, up to 20 mg | 883 | 531 | $9K |
| 88304 | 608 | 557 | $8K | |
| 86225 | 705 | 645 | $8K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 147 | 142 | $8K |
| Z7610 | 2,139 | 1,358 | $8K | |
| 82105 | 563 | 554 | $8K | |
| J7999 | Compounded drug, not otherwise classified | 202 | 184 | $8K |
| 88173 | 382 | 321 | $8K | |
| 90682 | 334 | 333 | $8K | |
| 86364 | 641 | 447 | $8K | |
| 87075 | 592 | 548 | $8K | |
| 76937 | 250 | 241 | $7K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 120 | 109 | $7K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 1,328 | 1,196 | $7K |
| 86304 | 584 | 515 | $7K | |
| 88142 | 1,366 | 1,356 | $7K | |
| 73701 | 12 | 12 | $7K | |
| 72128 | 12 | 12 | $7K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 60 | 60 | $7K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 131 | 125 | $7K |
| 84481 | 538 | 526 | $7K | |
| 89051 | 1,203 | 1,095 | $7K | |
| 92133 | 513 | 507 | $7K | |
| 90677 | 100 | 100 | $7K | |
| 99354 | 60 | 60 | $7K | |
| 86147 | 100 | 100 | $7K | |
| 76882 | 362 | 328 | $7K | |
| 87486 | 86 | 86 | $6K | |
| 87581 | 86 | 86 | $6K | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 328 | 275 | $6K |
| 80069 | 1,256 | 1,199 | $6K | |
| 0260 | 82 | 81 | $6K | |
| 84165 | 728 | 692 | $6K | |
| 77080 | 265 | 263 | $6K | |
| 82977 | 704 | 629 | $6K | |
| 71020 | 285 | 140 | $6K | |
| 82397 | 314 | 303 | $5K | |
| 82565 | 1,830 | 1,662 | $5K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | 281 | 204 | $5K |
| P9047 | Infusion, albumin (human), 25%, 50 ml | 49 | 15 | $5K |
| 67028 | Intravitreal injection of a pharmacologic agent | 122 | 117 | $5K |
| 97165 | 77 | 69 | $5K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 738 | 457 | $5K |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | 74 | 66 | $5K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 1,148 | 1,061 | $5K |
| 96402 | 494 | 442 | $5K | |
| 86787 | 561 | 550 | $5K | |
| 87536 | 104 | 98 | $5K | |
| 84153 | 424 | 403 | $5K | |
| 73200 | 25 | 24 | $5K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | 120 | 39 | $5K |
| 73070 | 159 | 139 | $5K | |
| 96900 | 501 | 93 | $5K | |
| 86146 | 84 | 84 | $5K | |
| 86800 | 415 | 380 | $4K | |
| 82043 | 1,540 | 1,527 | $4K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 814 | 810 | $4K |
| 92550 | 165 | 158 | $4K | |
| 94375 | 91 | 91 | $4K | |
| 91322 | 73 | 73 | $4K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 260 | 174 | $4K |
| 73100 | 155 | 122 | $4K | |
| 83883 | 309 | 293 | $4K | |
| 73521 | 142 | 141 | $4K | |
| 86255 | 213 | 206 | $4K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 40 | 40 | $4K |
| 86790 | 404 | 404 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 508 | 483 | $4K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 145 | 136 | $3K |
| 77001 | 54 | 54 | $3K | |
| 85384 | 343 | 277 | $3K | |
| 70250 | 52 | 50 | $3K | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | 15 | 14 | $3K |
| X4540 | 96 | 96 | $3K | |
| 83020 | 267 | 238 | $3K | |
| 86592 | 580 | 559 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 289 | 263 | $3K |
| 88360 | 145 | 102 | $3K | |
| 86431 | 423 | 421 | $3K | |
| 92526 | 89 | 78 | $3K | |
| J2997 | Injection, alteplase recombinant, 1 mg | 12 | 12 | $3K |
| J0571 | Buprenorphine, oral, 1 mg | 380 | 220 | $3K |
| 82010 | 266 | 250 | $3K | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | 27 | 25 | $3K |
| 92553 | 82 | 82 | $3K | |
| Z5916 | 56 | 55 | $3K | |
| J1171 | Injection, hydromorphone, 0.1 mg | 171 | 154 | $3K |
| 83021 | 151 | 119 | $3K | |
| 0730 | 232 | 219 | $3K | |
| 84550 | 786 | 667 | $3K | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 139 | 129 | $3K |
| 87517 | 193 | 188 | $3K | |
| 84425 | 450 | 447 | $3K | |
| 87102 | 326 | 309 | $3K | |
| C9113 | Injection, pantoprazole sodium, per vial | 167 | 133 | $3K |
| 86665 | 63 | 60 | $3K | |
| 85651 | 495 | 459 | $3K | |
| 95885 | 65 | 55 | $2K | |
| 86301 | 157 | 144 | $2K | |
| 82610 | 224 | 216 | $2K | |
| 86258 | 226 | 126 | $2K | |
| 97162 | 25 | 25 | $2K | |
| 51741 | 103 | 93 | $2K | |
| 86644 | 177 | 168 | $2K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 172 | 169 | $2K |
| 83001 | 172 | 166 | $2K | |
| 96156 | 25 | 24 | $2K | |
| 91200 | 152 | 151 | $2K | |
| 86376 | 180 | 178 | $2K | |
| 0272 | 116 | 93 | $2K | |
| 82525 | 332 | 329 | $2K | |
| 72195 | 12 | 12 | $2K | |
| 82670 | 115 | 111 | $2K | |
| 93880 | 12 | 12 | $2K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 879 | 837 | $2K |
| 92083 | 90 | 89 | $2K | |
| 86334 | 160 | 151 | $2K | |
| 82747 | 148 | 147 | $2K | |
| 00000 | 57 | 45 | $2K | |
| 74021 | 27 | 26 | $2K | |
| 83525 | 209 | 207 | $2K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 12 | 12 | $2K |
| 84590 | 320 | 320 | $2K | |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 82 | 25 | $2K |
| 84450 | 534 | 460 | $2K | |
| 77073 | 51 | 49 | $2K | |
| 80178 | 115 | 96 | $1K | |
| 76514 | 254 | 251 | $1K | |
| 93978 | 13 | 13 | $1K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 120 | 114 | $1K |
| 83993 | 114 | 114 | $1K | |
| 85613 | 132 | 115 | $1K | |
| 84630 | 359 | 355 | $1K | |
| 36561 | 12 | 12 | $1K | |
| 74220 | 40 | 40 | $1K | |
| 73501 | 40 | 37 | $1K | |
| 86762 | 183 | 178 | $1K | |
| 77065 | Tomosynthesis, mammo | 25 | 25 | $1K |
| 90656 | 151 | 151 | $1K | |
| 86200 | 176 | 176 | $1K | |
| 84155 | 587 | 560 | $1K | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 93 | 68 | $1K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 85 | 54 | $1K |
| 90480 | 77 | 77 | $1K | |
| Q3014 | Telehealth originating site facility fee | 136 | 127 | $1K |
| 85240 | 78 | 69 | $1K | |
| 97161 | 129 | 119 | $1K | |
| 0324 | 255 | 245 | $1K | |
| 83002 | 94 | 91 | $1K | |
| 86664 | 63 | 60 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 20 | 15 | $1K |
| 85246 | 39 | 38 | $1K | |
| 87529 | 17 | 17 | $1K | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | 419 | 378 | $996.30 |
| 71010 | 63 | 29 | $990.19 | |
| 83051 | 96 | 92 | $986.86 | |
| 96376 | 16 | 12 | $975.29 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | 69 | 44 | $972.32 |
| 86663 | 63 | 60 | $953.60 | |
| 0420 | 605 | 436 | $945.03 | |
| J1611 | Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg | 12 | 12 | $922.24 |
| Z5918 | 38 | 38 | $824.60 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 21 | 21 | $790.33 |
| Z4311 | 65 | 65 | $783.25 | |
| 73010 | 25 | 25 | $783.13 | |
| 82950 | 312 | 308 | $775.99 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 82 | 79 | $737.81 |
| 84146 | 91 | 91 | $737.44 | |
| 77066 | Tomosynthesis, mammo | 34 | 34 | $731.84 |
| 95874 | 85 | 81 | $711.58 | |
| 0115U | 13 | 13 | $689.72 | |
| Z4302 | 26 | 26 | $626.60 | |
| 82310 | 184 | 163 | $621.94 | |
| 92025 | 112 | 111 | $600.12 | |
| 0424 | 73 | 71 | $596.65 | |
| 0302 | 69 | 68 | $586.64 | |
| 95983 | 12 | 12 | $579.08 | |
| J9263 | Injection, oxaliplatin, 0.5 mg | 26 | 12 | $575.28 |
| 0307 | 288 | 278 | $570.85 | |
| 84134 | 57 | 55 | $564.14 | |
| 90662 | 216 | 212 | $560.82 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 24 | 15 | $555.36 |
| 87206 | 103 | 93 | $537.16 | |
| 82040 | 232 | 213 | $521.32 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 60 | 57 | $502.55 |
| 93297 | 208 | 206 | $478.37 | |
| 88312 | 45 | 36 | $458.92 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 86 | 83 | $455.72 |
| 64615 | 40 | 39 | $439.28 | |
| 74000 | 19 | 13 | $416.08 | |
| G0008 | Administration of influenza virus vaccine | 304 | 304 | $415.90 |
| 84305 | 65 | 62 | $411.47 | |
| 93298 | 44 | 44 | $407.69 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 194 | 171 | $393.58 |
| 85576 | 14 | 13 | $390.78 | |
| 85245 | 13 | 13 | $373.49 | |
| 80299 | 27 | 25 | $367.07 | |
| 88300 | 83 | 80 | $366.72 | |
| 86341 | 12 | 12 | $362.77 | |
| 97010 | 321 | 144 | $351.41 | |
| Q0112 | All potassium hydroxide (koh) preparations | 148 | 132 | $348.85 |
| 87116 | 14 | 12 | $336.04 | |
| 86593 | 66 | 65 | $321.31 | |
| 96150 | 12 | 12 | $303.05 | |
| 86355 | 14 | 14 | $301.44 | |
| 87210 | 149 | 143 | $297.39 | |
| 83527 | 36 | 36 | $291.74 | |
| 82180 | 27 | 27 | $291.04 | |
| 94664 | 15 | 14 | $276.21 | |
| Z5920 | 12 | 12 | $260.40 | |
| 97139 | 444 | 143 | $256.35 | |
| 82085 | 47 | 42 | $253.50 | |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | 34 | 12 | $239.70 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 30 | 15 | $238.63 |
| 0320 | 42 | 42 | $232.17 | |
| 84132 | 61 | 57 | $199.08 | |
| 73565 | 12 | 12 | $196.80 | |
| 86709 | 12 | 12 | $162.58 | |
| 82627 | 12 | 12 | $162.52 | |
| J1836 | Injection, metronidazole, 10 mg | 25 | 24 | $148.27 |
| H1003 | Prenatal care, at-risk enhanced service; education | 13 | 12 | $145.36 |
| 82150 | 25 | 25 | $142.12 | |
| 51705 | 39 | 36 | $128.50 | |
| 87015 | 14 | 12 | $128.03 | |
| 0124A | 12 | 12 | $120.00 | |
| 92250 | 24 | 24 | $119.45 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 15 | 15 | $110.53 |
| 80177 | 14 | 12 | $108.00 | |
| 84446 | 15 | 15 | $105.00 | |
| 82103 | 12 | 12 | $101.90 | |
| 84295 | 29 | 29 | $99.01 | |
| 90744 | 17 | 13 | $98.73 | |
| 83721 | 12 | 12 | $94.91 | |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 538 | 468 | $94.49 |
| 87324 | 14 | 14 | $90.50 | |
| 82435 | 25 | 25 | $90.06 | |
| 82272 | 16 | 16 | $89.83 | |
| 83930 | 14 | 13 | $83.18 | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 22 | 13 | $63.13 |
| J9260 | Injection, methotrexate sodium, 50 mg | 73 | 52 | $56.33 |
| 0402 | 24 | 24 | $52.24 | |
| 84207 | 14 | 14 | $35.00 | |
| 90732 | 13 | 13 | $34.50 | |
| 99459 | 13 | 13 | $30.42 | |
| 88311 | 13 | 12 | $29.71 | |
| 0352 | 91 | 91 | $0.00 | |
| 0258 | 152 | 147 | $0.00 | |
| 51798 | 28 | 28 | $0.00 | |
| 97810 | 64 | 27 | $0.00 |